Global Varicella Attenuated Live Vaccine Market Growth 2020-2025
According to this study, over the next five years the Varicella Attenuated Live Vaccine market will register a 4.4%% CAGR in terms of revenue, the global market size will reach $ 2763.5 million by 2025, from $ 2325.4 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Varicella Attenuated Live Vaccine business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Varicella Attenuated Live Vaccine market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Varicella Attenuated Live Vaccine, covering the supply chain analysis, impact assessment to the Varicella Attenuated Live Vaccine market size growth rate in several scenarios, and the measures to be undertaken by Varicella Attenuated Live Vaccine companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Monovalent Vaccine
Combination Vaccine
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Kids Injection
Adults Injection
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Merck
BCHT
GSK
Keygen
Shanghai Institute
Shanghai Rongsheng Biotech
Green Cross
Changchun Changsheng Life Sciences Limited
Biken
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Varicella Attenuated Live Vaccine consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Varicella Attenuated Live Vaccine market by identifying its various subsegments.
Focuses on the key global Varicella Attenuated Live Vaccine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Varicella Attenuated Live Vaccine with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Varicella Attenuated Live Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Varicella Attenuated Live Vaccine Consumption 2015-2025
2.1.2 Varicella Attenuated Live Vaccine Consumption CAGR by Region
2.2 Varicella Attenuated Live Vaccine Segment by Type
2.2.1 Monovalent Vaccine
2.2.2 Combination Vaccine
2.3 Varicella Attenuated Live Vaccine Consumption by Type
2.3.1 Global Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
2.3.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Type (2015-2020)
2.3.3 Global Varicella Attenuated Live Vaccine Sale Price by Type (2015-2020)
2.4 Varicella Attenuated Live Vaccine Segment by Application
2.4.1 Kids Injection
2.4.2 Adults Injection
2.5 Varicella Attenuated Live Vaccine Consumption by Application
2.5.1 Global Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
2.5.2 Global Varicella Attenuated Live Vaccine Value and Market Share by Type (2015-2020)
2.5.3 Global Varicella Attenuated Live Vaccine Sale Price by Type (2015-2020)
3 Global Varicella Attenuated Live Vaccine by Company
3.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Company
3.1.1 Global Varicella Attenuated Live Vaccine Sales by Company (2018-2020)
3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2018-2020)
3.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Company
3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Company (2018-2020)
3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2018-2020)
3.3 Global Varicella Attenuated Live Vaccine Sale Price by Company
3.4 Global Varicella Attenuated Live Vaccine Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Varicella Attenuated Live Vaccine Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Varicella Attenuated Live Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Varicella Attenuated Live Vaccine by Regions
4.1 Varicella Attenuated Live Vaccine by Regions
4.2 Americas Varicella Attenuated Live Vaccine Consumption Growth
4.3 APAC Varicella Attenuated Live Vaccine Consumption Growth
4.4 Europe Varicella Attenuated Live Vaccine Consumption Growth
4.5 Middle East & Africa Varicella Attenuated Live Vaccine Consumption Growth
5 Americas
5.1 Americas Varicella Attenuated Live Vaccine Consumption by Countries
5.1.1 Americas Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020)
5.1.2 Americas Varicella Attenuated Live Vaccine Value by Countries (2015-2020)
5.2 Americas Varicella Attenuated Live Vaccine Consumption by Type
5.3 Americas Varicella Attenuated Live Vaccine Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Varicella Attenuated Live Vaccine Consumption by Regions
6.1.1 APAC Varicella Attenuated Live Vaccine Consumption by Regions (2015-2020)
6.1.2 APAC Varicella Attenuated Live Vaccine Value by Regions (2015-2020)
6.2 APAC Varicella Attenuated Live Vaccine Consumption by Type
6.3 APAC Varicella Attenuated Live Vaccine Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Varicella Attenuated Live Vaccine by Countries
7.1.1 Europe Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020)
7.1.2 Europe Varicella Attenuated Live Vaccine Value by Countries (2015-2020)
7.2 Europe Varicella Attenuated Live Vaccine Consumption by Type
7.3 Europe Varicella Attenuated Live Vaccine Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Varicella Attenuated Live Vaccine by Countries
8.1.1 Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Varicella Attenuated Live Vaccine Value by Countries (2015-2020)
8.2 Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Type
8.3 Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Varicella Attenuated Live Vaccine Distributors
10.3 Varicella Attenuated Live Vaccine Customer
11 Global Varicella Attenuated Live Vaccine Market Forecast
11.1 Global Varicella Attenuated Live Vaccine Consumption Forecast (2021-2025)
11.2 Global Varicella Attenuated Live Vaccine Forecast by Regions
11.2.1 Global Varicella Attenuated Live Vaccine Forecast by Regions (2021-2025)
11.2.2 Global Varicella Attenuated Live Vaccine Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast byRegions
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Varicella Attenuated Live Vaccine Forecast by Type
11.8 Global Varicella Attenuated Live Vaccine Forecast by Application
12 Key Players Analysis
12.1 Merck
12.1.1 Company Information
12.1.2 Varicella Attenuated Live Vaccine Product Offered
12.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Merck Latest Developments
12.2 BCHT
12.2.1 Company Information
12.2.2 Varicella Attenuated Live Vaccine Product Offered
12.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 BCHT Latest Developments
12.3 GSK
12.3.1 Company Information
12.3.2 Varicella Attenuated Live Vaccine Product Offered
12.3.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GSK Latest Developments
12.4 Keygen
12.4.1 Company Information
12.4.2 Varicella Attenuated Live Vaccine Product Offered
12.4.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Keygen Latest Developments
12.5 Shanghai Institute
12.5.1 Company Information
12.5.2 Varicella Attenuated Live Vaccine Product Offered
12.5.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Shanghai Institute Latest Developments
12.6 Shanghai Rongsheng Biotech
12.6.1 Company Information
12.6.2 Varicella Attenuated Live Vaccine Product Offered
12.6.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Shanghai Rongsheng Biotech Latest Developments
12.7 Green Cross
12.7.1 Company Information
12.7.2 Varicella Attenuated Live Vaccine Product Offered
12.7.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Green Cross Latest Developments
12.8 Changchun Changsheng Life Sciences Limited
12.8.1 Company Information
12.8.2 Varicella Attenuated Live Vaccine Product Offered
12.8.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Changchun Changsheng Life Sciences Limited Latest Developments
12.9 Biken
12.9.1 Company Information
12.9.2 Varicella Attenuated Live Vaccine Product Offered
12.9.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Biken Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Varicella Attenuated Live Vaccine Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Monovalent Vaccine
Table 5. Major Players of Combination Vaccine
Table 6. Global Consumption Sales by Type (2015-2020)
Table 7. Global Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Table 8. Global Varicella Attenuated Live Vaccine Revenue by Type (2015-2020) ($ million)
Table 9. Global Varicella Attenuated Live Vaccine Value Market Share by Type (2015-2020) ($ Millions)
Table 10. Global Varicella Attenuated Live Vaccine Sale Price by Type (2015-2020)
Table 11. Global Consumption Sales by Application (2015-2020)
Table 12. Global Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Table 13. Global Varicella Attenuated Live Vaccine Value by Application (2015-2020)
Table 14. Global Varicella Attenuated Live Vaccine Value Market Share by Application (2015-2020)
Table 15. Global Varicella Attenuated Live Vaccine Sale Price by Application (2015-2020)
Table 16. Global Varicella Attenuated Live Vaccine Sales by Company (2017-2019) (K Doses)
Table 17. Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2017-2019)
Table 18. Global Varicella Attenuated Live Vaccine Revenue by Company (2017-2019) ($ Millions)
Table 19. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2017-2019)
Table 20. Global Varicella Attenuated Live Vaccine Sale Price by Company (2017-2019)
Table 21. Global Varicella Attenuated Live Vaccine Manufacturing Base Distribution and Sales Area by Manufacturers
Table 22. Players Varicella Attenuated Live Vaccine Products Offered
Table 23. Varicella Attenuated Live Vaccine Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 24. Global Varicella Attenuated Live Vaccine Consumption by Regions 2015-2020 (K Doses)
Table 25. Global Varicella Attenuated Live Vaccine Consumption Market Share by Regions 2015-2020
Table 26. Global Varicella Attenuated Live Vaccine Value by Regions 2015-2020 ($ Millions)
Table 27. Global Varicella Attenuated Live Vaccine Value Market Share by Regions 2015-2020
Table 28. Americas Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020) (K Doses)
Table 29. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Countries (2015-2020)
Table 30. Americas Varicella Attenuated Live Vaccine Value by Countries (2015-2020) ($ Millions)
Table 31. Americas Varicella Attenuated Live Vaccine Value Market Share by Countries (2015-2020)
Table 32. Americas Varicella Attenuated Live Vaccine Consumption by Type (2015-2020) (K Doses)
Table 33. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Table 34. Americas Varicella Attenuated Live Vaccine Consumption by Application (2015-2020) (K Doses)
Table 35. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Table 36. APAC Varicella Attenuated Live Vaccine Consumption by Regions (2015-2020) (K Doses)
Table 37. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Regions (2015-2020)
Table 38. APAC Varicella Attenuated Live Vaccine Value by Regions (2015-2020) ($ Millions)
Table 39. APAC Varicella Attenuated Live Vaccine Value Market Share by Regions (2015-2020)
Table 40. APAC Varicella Attenuated Live Vaccine Consumption by Type (2015-2020) (K Doses)
Table 41. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Table 42. APAC Varicella Attenuated Live Vaccine Consumption by Application (2015-2020) (K Doses)
Table 43. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Table 44. Europe Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020) (K Doses)
Table 45. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Countries (2015-2020)
Table 46. Europe Varicella Attenuated Live Vaccine Value by Countries (2015-2020) ($ Millions)
Table 47. Europe Varicella Attenuated Live Vaccine Value Market Share by Countries (2015-2020)
Table 48. Europe Varicella Attenuated Live Vaccine Consumption by Type (2015-2020) (K Doses)
Table 49. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Table 50. Europe Varicella Attenuated Live Vaccine Consumption by Application (2015-2020) (K Doses)
Table 51. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Table 52. Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Countries (2015-2020) (K Doses)
Table 53. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Countries (2015-2020)
Table 54. Middle East & Africa Varicella Attenuated Live Vaccine Value by Countries (2015-2020) ($ Millions)
Table 55. Middle East & Africa Varicella Attenuated Live Vaccine Value Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Type (2015-2020) (K Doses)
Table 57. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Table 58. Middle East & Africa Varicella Attenuated Live Vaccine Consumption by Application (2015-2020) (K Doses)
Table 59. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Table 60. Varicella Attenuated Live Vaccine Distributors List
Table 61. Varicella Attenuated Live Vaccine Customer List
Table 62. Global Varicella Attenuated Live Vaccine Consumption Forecast by Countries (2021-2025) (K Doses)
Table 63. Global Varicella Attenuated Live Vaccine Consumption Market Forecast by Regions
Table 64. Global Varicella Attenuated Live Vaccine Value Forecast by Countries (2021-2025) ($ Millions)
Table 65. Global Varicella Attenuated Live Vaccine Value Market Share Forecast by Regions
Table 66. Global Varicella Attenuated Live Vaccine Consumption Forecast by Type (2021-2025) (K Doses)
Table 67. Global Varicella Attenuated Live Vaccine Consumption Market Share Forecast by Type (2021-2025)
Table 68. Global Varicella Attenuated Live Vaccine Value Forecast by Type (2021-2025) ($ Millions)
Table 69. Global Varicella Attenuated Live Vaccine Value Market Share Forecast by Type (2021-2025)
Table 70. Global Varicella Attenuated Live Vaccine Consumption Forecast by Application (2021-2025) (K Doses)
Table 71. Global Varicella Attenuated Live Vaccine Consumption Market Share Forecast by Application (2021-2025)
Table 72. Global Varicella Attenuated Live Vaccine Value Forecast by Application (2021-2025) ($ Millions)
Table 73. Global Varicella Attenuated Live Vaccine Value Market Share Forecast by Application (2021-2025)
Table 74. Merck Product Offered
Table 75. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 76. Merck Main Business
Table 77. Merck Latest Developments
Table 78. Merck Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. BCHT Product Offered
Table 80. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 81. BCHT Main Business
Table 82. BCHT Latest Developments
Table 83. BCHT Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Product Offered
Table 85. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. GSK Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Keygen Product Offered
Table 90. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 91. Keygen Main Business
Table 92. Keygen Latest Developments
Table 93. Keygen Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Shanghai Institute Product Offered
Table 95. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 96. Shanghai Institute Main Business
Table 97. Shanghai Institute Latest Developments
Table 98. Shanghai Institute Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Shanghai Rongsheng Biotech Product Offered
Table 100. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 101. Shanghai Rongsheng Biotech Main Business
Table 102. Shanghai Rongsheng Biotech Latest Developments
Table 103. Shanghai Rongsheng Biotech Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Green Cross Product Offered
Table 105. Green Cross Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 106. Green Cross Main Business
Table 107. Green Cross Latest Developments
Table 108. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 109. Changchun Changsheng Life Sciences Limited Product Offered
Table 110. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 111. Changchun Changsheng Life Sciences Limited Main Business
Table 112. Changchun Changsheng Life Sciences Limited Latest Developments
Table 113. Changchun Changsheng Life Sciences Limited Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Biken Product Offered
Table 115. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 116. Biken Main Business
Table 117. Biken Latest Developments
Table 118. Biken Basic Information, Company Total Revenue (in $ million), Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Varicella Attenuated Live Vaccine
Figure 2. Varicella Attenuated Live Vaccine Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Varicella Attenuated Live Vaccine Consumption Growth Rate 2015-2025 (K Doses)
Figure 5. Global Varicella Attenuated Live Vaccine Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Monovalent Vaccine
Figure 7. Product Picture of Combination Vaccine
Figure 8. Global Varicella Attenuated Live Vaccine Consumption Market Share by Type (2015-2020)
Figure 9. Global Varicella Attenuated Live Vaccine Value Market Share by Type (2015-2020)
Figure 10. Varicella Attenuated Live Vaccine Consumed in Kids Injection
Figure 11. Global Varicella Attenuated Live Vaccine Market: Kids Injection (2015-2020) (K Doses)
Figure 12. Global Varicella Attenuated Live Vaccine Market: Kids Injection (2015-2020) ($ Millions)
Figure 13. Varicella Attenuated Live Vaccine Consumed in Adults Injection
Figure 14. Global Varicella Attenuated Live Vaccine Market: Adults Injection (2015-2020) (K Doses)
Figure 15. Global Varicella Attenuated Live Vaccine Market: Adults Injection (2015-2020) ($ Millions)
Figure 16. Global Varicella Attenuated Live Vaccine Consumption Market Share by Application (2015-2020)
Figure 17. Global Varicella Attenuated Live Vaccine Value Market Share by Application (2015-2020)
Figure 18. Global Varicella Attenuated Live Vaccine Sales Market Share by Company in 2017
Figure 19. Global Varicella Attenuated Live Vaccine Sales Market Share by Company in 2019
Figure 20. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company in 2017
Figure 21. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company in 2019
Figure 22. Global Varicella Attenuated Live Vaccine Sale Price by Company in 2019
Figure 23. Global Varicella Attenuated Live Vaccine Consumption Market Share by Regions 2015-2020
Figure 24. Global Varicella Attenuated Live Vaccine Value Market Share by Regions 2015-2020
Figure 25. Americas Varicella Attenuated Live Vaccine Consumption 2015-2020 (K Doses)
Figure 26. Americas Varicella Attenuated Live Vaccine Value 2015-2020 ($ Millions)
Figure 27. APAC Varicella Attenuated Live Vaccine Consumption 2015-2020 (K Doses)
Figure 28. APAC Varicella Attenuated Live Vaccine Value 2015-2020 ($ Millions)
Figure 29. Europe Varicella Attenuated Live Vaccine Consumption 2015-2020 (K Doses)
Figure 30. Europe Varicella Attenuated Live Vaccine Value 2015-2020 ($ Millions)
Figure 31. Middle East & Africa Varicella Attenuated Live Vaccine Consumption 2015-2020 (K Doses)
Figure 32. Middle East & Africa Varicella Attenuated Live Vaccine Value 2015-2020 ($ Millions)
Figure 33. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Countries in 2019
Figure 34. Americas Varicella Attenuated Live Vaccine Value Market Share by Countries in 2019
Figure 35. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Type in 2019
Figure 36. Americas Varicella Attenuated Live Vaccine Consumption Market Share by Application in 2019
Figure 37. United States Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 38. United States Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 39. Canada Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 40. Canada Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 41. Mexico Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 42. Mexico Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 43. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Countries in 2019
Figure 44. APAC Varicella Attenuated Live Vaccine Value Market Share by Regions in 2019
Figure 45. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Type in 2019
Figure 46. APAC Varicella Attenuated Live Vaccine Consumption Market Share by Application in 2019
Figure 47. China Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 48. China Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 49. Japan Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 50. Japan Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 51. Korea Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 52. Korea Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 53. Southeast Asia Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 54. Southeast Asia Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 55. India Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 56. India Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 57. Australia Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 58. Australia Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 59. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Countries in 2019
Figure 60. Europe Varicella Attenuated Live Vaccine Value Market Share by Countries in 2019
Figure 61. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Type in 2019
Figure 62. Europe Varicella Attenuated Live Vaccine Consumption Market Share by Application in 2019
Figure 63. Germany Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 64. Germany Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 65. France Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 66. France Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 67. UK Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 68. UK Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 69. Italy Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 70. Italy Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 71. Russia Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 72. Russia Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 73. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Countries in 2019
Figure 74. Middle East & Africa Varicella Attenuated Live Vaccine Value Market Share by Countries in 2019
Figure 75. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Type in 2019
Figure 76. Middle East & Africa Varicella Attenuated Live Vaccine Consumption Market Share by Application in 2019
Figure 77. Egypt Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 78. Egypt Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 79. South Africa Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 80. South Africa Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 81. Israel Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 82. Israel Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 83. Turkey Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 84. Turkey Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 85. GCC Countries Varicella Attenuated Live Vaccine Consumption Growth 2015-2020 (K Doses)
Figure 86. GCC Countries Varicella Attenuated Live Vaccine Value Growth 2015-2020 ($ Millions)
Figure 87. Global Varicella Attenuated Live Vaccine Consumption Growth Rate Forecast (2021-2025) (K Doses)
Figure 88. Global Varicella Attenuated Live Vaccine Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 89. Americas Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 90. Americas Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 91. APAC Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 92. APAC Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 93. Europe Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 94. Europe Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 95. Middle East & Africa Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 96. Middle East & Africa Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 97. United States Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 98. United States Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 99. Canada Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 100. Canada Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 101. Mexico Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 102. Mexico Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 103. Brazil Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 104. Brazil Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 105. China Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 106. China Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 107. Japan Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 108. Japan Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 109. Korea Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 110. Korea Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 111. Southeast Asia Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 112. Southeast Asia Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 113. India Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 114. India Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 115. Australia Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 116. Australia Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 117. Germany Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 118. Germany Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 119. France Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 120. France Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 121. UK Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 122. UK Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 123. Italy Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 124. Italy Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 125. Russia Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 126. Russia Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 127. Spain Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 128. Spain Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 129. Egypt Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 130. Egypt Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 131. South Africa Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 132. South Africa Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 133. Israel Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 134. Israel Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 135. Turkey Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 136. Turkey Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 137. GCC Countries Varicella Attenuated Live Vaccine Consumption 2021-2025 (K Doses)
Figure 138. GCC Countries Varicella Attenuated Live Vaccine Value 2021-2025 ($ Millions)
Figure 139. Merck Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 140. BCHT Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 141. GSK Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 142. Keygen Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 143. Shanghai Institute Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 144. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 145. Green Cross Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 146. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Market Share (2018-2020)
Figure 147. Biken Varicella Attenuated Live Vaccine Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets